Cemiplimab Gains Breakthrough Tx Designation for Advanced Skin Cancer
A Phase 2, single-arm, open-label clinical trial, EMPOWER-CSCC 1, is now enrolling patients with metastatic CSCC and locally advanced and unresectable CSCC.
Skin Cancer
MITF p.E318K Prevalence Similar, Regardless of CDKN2A
The prevalence of MITF p.E318K is similar in patients with melanoma, irrespective of the presence of CDKN2A mutations, according to a study published online in JAMA Dermatology.
Study Examines Incidence of Non-Melanoma Skin Cancer
Incidence of NMSC much higher among Caucasians; Hispanic patients significantly younger
C-Reactive Protein Independent Prognostic Marker in Melanoma
Link with overall, melanoma-specific survival; increase in CRP also linked to disease progression
Teledermoscopy Effective for Monitoring Nevi
Diagnostic concordance 0.87 between conventional office-based visits, teledermoscopy encounters
